Summary According to current textbook wisdom the liver is the exclusive site of glucose production in humans in the postabsorptive state. Although many animal and in vitro data have documented that the kidney is capable of gluconeogenesis, production of glucose by the human kidney in the postabsorptive state has generally been regarded as negligible. This traditional view is based on net balance measurements which, other than after a prolonged fast or during metabolic acidosis, showed no significant net renal glucose release. However, recent studies have refuted this view by combining isotopic and balance techniques, which have demonstrated that renal glucose production accounts for 25 % of systemic glucose production. Moreover, these studies indicate that glucose production by the human kidney is stimulated by epinephrine, inhibited by insulin and is excessive in diabetes mellitus. Since renal glucose release is largely, if not exclusively, due to gluconeogenesis, it is likely that the kidney is as important a gluconeogenic organ as the liver. The most important renal gluconeogenic precursors appear to be lactate, glutamine and glycerol. The implications of these recent findings on the understanding of the physiology and pathophysiology of human glucose metabolism are discussed. [Diabetologia (1997) 40: 749-757].
In the postabsorptive state, glucose must be continuously delivered into the circulation in order to meet energy requirements of tissues such as brain cells and erythrocytes, which use only glucose as their fuel. Only liver and kidney are able to release glucose into the circulation because other tissues lack glucose 6-phosphatase [1] . Release of glucose into the circulation occurs via two processes: gluconeogenesis, the de novo synthesis of glucose from non-glucose precursors; and glycogenolysis, the breakdown of glycogen, a carbohydrate polymer formed directly from glucose or indirectly via gluconeogenesis [2] . Current evidence indicates that in postabsorptive normal humans (overnight fasted state) gluconeogenesis and glycogenolysis each contribute approximately 50 % of the glucose delivered into the systemic circulation [3] .
It has long been recognized that on a gram-forgram tissue basis, the gluconeogenic capacity of the kidney exceeds that of the liver [4] . Nevertheless, based on net balance experiments finding no significant difference in arterial and renal vein glucose concentrations in the basal state [5] [6] [7] , until recently the human kidney has generally been regarded as contributing insignificantly to postabsorptive glucose production [8] [9] [10] . However, recent studies of renal glucose metabolism employing isotope techniques in vivo which permit individual assessment of glucose production and utilization, have clearly demonstrated that the kidney makes an appreciable contribution to both systemic glucose production and glucose utilization [11] [12] [13] . Diabetologia (1997) 
Historical aspects
In vitro and animal studies. The ability of mammalian kidney to synthesize glucose from non-carbohydrate precursors was demonstrated in vitro 60 years ago by Benoy and Elliot [14] , who observed that addition of lactate and pyruvate to kidney cortex slices increased the glucose concentration of the medium. In 1938, Bergman and Drury [15] observed that rabbits, which had been both hepatectomized and nephrectomized, required more exogenous glucose to maintain the normal blood glucose level than animals which had undergone hepatectomy alone. Interestingly, the authors did not conclude that the kidney makes glucose but rather that the kidney normally excretes a substance that if retained in the body causes a marked increase in the glucose requirement. In the 1940 s, net renal glucose release was found to increase in rats during hypoglycaemia after hepatectomy [16] and a greater rate of fall of blood glucose in dogs that had undergone nephrectomy with hepatectomy compared to hepatectomy only [17] . In the early 1950 s numerous in vitro studies further substantiated the gluconeogenic capacity of renal cortical tissue [18] [19] [20] .
Human studies. The first evidence for glucose production by the human kidney originates from the year 1966, when Aber et al. [21] showed substantial net renal glucose release of as much as 880 m mol/min in patients with severe chronic respiratory acidosis and also a lesser amount in non-acidotic subjects. This study nevertheless has generally been interpreted to indicate that net renal glucose release only occurred in subjects with acidosis. Three years later, Owen et al. [22] documented that net renal glucose output, though negligible in the postabsorptive state, contributed nearly 50 % to systemic glucose appearance after 4-6 weeks of fasting. Studies during the following three decades, did not find net renal glucose release in excess of 10 % of systemic glucose appearance under physiological conditions (Table 1) . These observations led to the traditional perception of the human kidney as playing a minor role in carbohydrate metabolism [9, 23] .
Methodological considerations
The study of renal substrate metabolism in general is complicated by the high rate of renal blood flow, usually reported in the range of 1200 and 1800 ml/min. This results in a very small arteriovenous difference for substrate concentrations, and presents an analytical challenge. The same applies to splanchnic balance studies, where blood flow is equally high and arteriovenous differences similarly small. Use of high-performance liquid chromatography (HPLC), which permits precise determination of arteriovenous differences in plasma concentrations and specific activities [24, 25] has helped to minimize this problem.
The conclusions drawn in previous studies (Table 1) which led to the traditional view that the human kidney releases insignificant amounts of glucose, were based on net balance data of glucose, i. e. the mathematical product of arterio-renal venous difference of glucose concentrations (mmol/ml, obtained through a sampling catheter in a renal vein) and renal blood flow (ml/min). The net balance approach, however, does not take into consideration simultaneous release and uptake of glucose by the kidney. Uptake and release are distinct processes subject to separate regulation and occurring in different locations within the kidney. Glucose utilization occurs predominantly in the renal medulla, whereas glucose production is confined to the cortex [23, [26] [27] [28] (Fig. 1) . Thus, by merely representing the difference between uptake and release of a substrate, net balance measurements cannot evaluate the contribution of an organ to the entry and removal of a substrate from the systemic circulation. Moreover, inferences based on net balance measurements may lead to an underestimation of the role of an organ in the overall metabolism of a substrate. For example, with isotope dilution determination of systemic glucose flux, entry of glucose into the circulation is quantified by the dilution of the plasma glucose tracer concentration by unlabelled glucose released into the circulation [29] . If the kidney were to take up and release glucose at equal rates, there would be no arterio-renal venous glucose difference, and net glucose balance would be zero. Nevertheless, release of unlabelled glucose into the circulation by the kidney would dilute the plasma glucose tracer concentration and contribute to the isotopic estimation of glucose entry into the circulation (Fig. 2) . Similar considerations are true for the contribution of the kidney to removal of glucose from the circulation as determined isotopically. Therefore, a combination of net balance and isotopic techniques with measurement of substrate as well as tracer concentrations is necessary to assess individually the uptake and release of a substrate by an organ [29] [30] [31] .
Uptake and release of glucose by the kidney As indicated above, because the kidney uses and produces glucose, only a combination of isotopic and net balance techniques can provide a reliable assessment of renal glucose release. In 1978, Kida et al. [32] found a renal contribution of 25 % to systemic glucose production in rats by injecting a bolus of [ ]glucose concentration following hepatectomy. In intact animals the isotopic net balance approach was not employed until recently, when a significant renal uptake of glucose was shown in dogs accounting for as much as 30 % of glucose removal from the circulation under postabsorptive conditions [11, 12] . Since renal net balance was within the expected range, i. e. close to zero, the data also indicated that the kidney was responsible for over 20 % of glucose entry into plasma in postabsorptive dogs (Table 2 ).
An analogous approach was recently used in healthy, postabsorptive humans [13] . These studies showed, as expected, that the human kidney simultaneously takes up and releases appreciable amounts of glucose. Renal glucose release accounted for about 25 % of all glucose released into the circulation and its uptake of glucose accounted for approximately 20 % of all glucose removed from the circulation [13] ( Table 2) . These results thus refuted textbook wisdom that the human kidney plays a minor role in glucose homeostasis.
Regarding the mechanism for renal glucose release, the normal human kidney does not contain appreciable glycogen stores [33] . Moreover, renal cells which have appreciable glucose phosphorylating capacity and thus the ability to accumulate glycogen have relatively little glucose 6-phosphatase activity, whereas cells having little phosphorylating capacity possess abundant activity of glucose 6-phosphatase and other gluconeogenic enzymes [28, 34] . It is thus likely that release of glucose by the normal kidney is due mainly if not exclusively to gluconeogenesis. Consistent with this conclusion is the fact that the reported net renal uptake of key gluconeogenic precursors (e. g. lactate, glycerol, glutamine and other amino acids) is sufficient to account for all of the observed release of glucose by the kidney [5] [6] [7] .
Hormonal regulation of renal glucose production
In vitro studies in isolated, perfused animal kidneys and cortex slices indicate that hepatic and renal glucose release differ with respect to nutritional, acid-base-balance and hormonal influences as reviewed elsewhere [26] (Table 3) . Since this review deals with in vivo studies in humans, we will highlight recent observations of hormonal effects on glucose production by the human kidney.
Insulin. Many studies have shown that insulin inhibits gluconeogenesis in vitro in kidney cortex slices [35] and in vivo in diabetic animals treated with insulin [32] . The observation in humans that during euglycaemic-hyperinsulinaemic clamp experiments systemic glucose appearance, the sum of hepatic plus renal, decreases virtually to zero [36] strongly suggests that insulin suppresses renal glucose production in humans. In normal dogs intra-renal infusion of insulin, designed not to suppress systemic glucose appearance, decreased renal glucose production of the infused kidney by about 75 % [12] . Whether an analogous mechanism is operative in normal humans has not been directly assessed. Nevertheless, in a study using a combination of net balance and isotopes, repletion of insulin suppressed increased renal glucose production in insulin-dependent diabetic (IDDM) patients by 50 %, while decreasing hepatic glucose production by 80 % [37] . This suggests that in diabetes, at least, the kidney is less sensitive to the suppressive effect of insulin on glucose production than is the liver.
Glucagon. In vitro studies suggest that glucagon does not stimulate renal gluconeogenesis [38] . Infusion of glucagon designed to increase plasma glucagon concentrations threefold in normal volunteers had no effect on renal glucose production measured isotopically while doubling hepatic glucose production [39] . This is consistent with a previous report where suppression of glucagon secretion by infusion of somatostatin in fasted humans inhibited net splanchnic but not net renal glucose release [5] .
Epinephrine. Catecholamines have been shown to stimulate gluconeogenesis in isolated renal cortical tissue [40] . Moreover, infusion of epinephrine has been shown to accelerate systemic glucose production in humans [41] . In a recent study in healthy humans, designed to measure renal glucose production isotopically, epinephrine acutely increased systemic glucose production by 60 %, hepatic glucose release by 50 % and renal glucose production by 100 % [13] . It is of note that in this study, infusion of epinephrine, which resulted in circulating concentrations of epinephrine similar to those observed during hypoglycaemia [42] , caused a sustained increase in renal glucose release that after 3 h accounted for essentially all of the increased appearance of glucose in the circulation (Fig. 3) . The stimulatory effect of epinephrine on renal glucose production could be direct via In vitro and animal data summarized from [26, 27] cAMP-mediated stimulation of renal key gluconeogenic enzymes, as shown in vitro [40], or indirect through increased substrate availability since epinephrine has been shown to increase the availability of gluconeogenic precursors [41].
Other hormones. There are animal studies showing the effects of growth hormone, thyroxine, glucocorticoids and other hormones on renal glucose metabolism (Table 3 ), but to date no human data are available.
Renal gluconeogenic substrates
In humans, lactate, glutamine, alanine and glycerol are the main gluconeogenic precursors [2] . Based on splanchnic net balance measurements, however, uptake of these precursors by the liver can only account for 50 % of total gluconeogenesis [43] assuming gluconeogenesis to be 50 % of overall glucose production (i. e. gluconeogenesis plus glycogenolysis). In vitro studies have suggested lactate, pyruvate, glycerol, fructose, proprionate and certain amino acids including glutamine, glutamate and proline as potential renal precursor candidates [27] . Studies of uptake of potential gluconeogenic precursors by the human kidney have shown net uptake of glutamine and glycerol, but essentially no arteriovenous difference for alanine [5] [6] [7] . Moreover, infusion of glycerol has been reported to increase renal glucose output whereas infusion of alanine has not [6] . Human net balance data for lactate are somewhat controversial, ranging from virtually zero [7] to significant net uptake after a 60-h fast [5] (Table 1) . However, to quantitatively evaluate the potential role of renal gluconeogenic precursors, one must measure their conversion to glucose by the kidney [29] . Conversion of 14 C-labelled glycerol to glucose by the canine kidney has been demonstrated to contribute 10 % to renal gluconeogenesis [12] .
In vitro studies indicate that glutamine is one of the main gluconeogenic precursors used by the kidney [44] [45] [46] [47] . Recent observations suggest that in humans fasted overnight, approximately equal amounts of glucose are made gluconeogenetically from glutamine and alanine [48] . However, the human liver, has been reported to take up very little or no glutamine [49-51] whereas glutamine accounts for approximately 60 % of all amino acids taken up by human kidneys [7] . Using [U- 14 C]glutamine and determining the rate of conversion of glutamine to glucose directly via a renal vein catheter, it has been shown that in humans fasted overnight almost 80 % of systemic glutamine gluconeogenesis takes place in the kidney and that 15-20 % of renal glucose production is accounted for by renal glutamine gluconeogenesis [39] . Alanine on the other hand, was not converted to glucose by the kidney and thus alanine gluconeogenesis occurred exclusively in the liver [52] . This indicates gluconeogenic substrate selectivity of kidney and liver for glutamine and alanine, respectively, in humans (Fig. 4) . No tracer data for other substrates in humans are available.
Diabetes mellitus
It has long been known that renal glucose metabolism is altered in animals rendered diabetic experimentally [53, 54] . In alloxan-diabetic rats renal gluconeogenesis was increased twofold compared to normal rats [32] . Several issues regarding the underlying mechanism, however, have remained controversial. To what extent the accelerated renal gluconeogenesis is due to acidosis accompanying insulin-deficient diabetes [55] , to altered substrate availability [56] or to stimulation of gluconeogenic enzymes [55, 57] . Since diabetic kidneys contain measurable amounts of glycogen [33] , conceivably, not all of the release of glucose might be due to gluconeogenesis. To date there have been only two studies in IDDM patients evaluating renal glucose metabolism [37, 58] . In both there was substantial net uptake of glucose. The one isotopic study permitting independent determination of production and utilization of glucose, showed that although there was net renal glucose uptake renal glucose production in IDDM patients was increased proportionately to systemic glucose appearance [37] . To date no data in non-insulin-dependent (NIDDM) patients are available. However, indirect evidence for accelerated renal glucose production in this condition comes from the recent observation that systemic glutamine gluconeogenesis is increased in NIDDM patients [59] . If most of the glutamine conversion to glucose occurs in the kidney, as it does in normal subjects [39] , these data would indicate that renal glutamine gluconeogenesis is increased in NIDDM.
Implications for the understanding of human carbohydrate metabolism
The results obtained so far in humans have several implications for the understanding of human carbohydrate metabolism. The observations that in humans renal glucose production contributes approximately 25 % to systemic glucose production and renal glucose uptake accounts for 20 % of systemic glucose removal indicate an important role of the human kidney for glucose homeostasis. Essentially all renal glucose production comes from gluconeogenesis and gluconeogenesis accounts for about 50 % of systemic glucose production. Therefore, in contrast to current opinion, the kidney contributes as much as the liver to overall gluconeogenesis. However, since the kidney simultaneously utilizes glucose in terms of net addition to plasma of glucose made gluconeogenetically, its contribution is half that of the liver.
Most metabolic experiments in humans have used tracer dilution techniques for the study of hepatic glucose production [29] , assuming an insignificant contribution from the kidney. However, since the kidney contributes substantially to glucose turnover in the basal state and to an unknown extent during experimental perturbation or in pathological states, endogenous glucose production can no longer be assumed to equal hepatic glucose production.
Renal glucose production accounting for a quarter of all systemic glucose appearance should contribute significantly to the maintenance of normoglycaemia. This observation thus provides a possible explanation of why people with chronic renal failure are prone to develop hypoglycaemia [60] [61] [62] [63] . Moreover, the stimulation of glucose release by epinephrine suggests an important role of the kidney in glucose counterregulation [64] . Finally, infusion of ethanol, known to inhibit whole body gluconeogenesis in humans [65] , caused a mild hypoglycaemic response and a significant increase in net renal glucose release in dogs [66] . This suggests that ethanol selectively inhibits hepatic gluconeogenesis.
The association of uraemia and insulin resistance has long been recognized, although the exact pathogenesis is not fully understood [67] . The effects of uraemia on glucose production have not been unanimously established [68] [69] [70] , since it is likely that offsetting mechanisms are operative. On the one hand, uraemia could induce hepatic insulin resistance whereby decreased insulin suppression of basal hepatic glucose production would result in an increase in glucose turnover. On the other hand, loss of renal glucose production would lead to a decrease in glucose appearance and insulin sensitivity.
The uptake of glucose by the kidney in the postabsorptive state is comparable to that reported for skeletal muscle [71, 72] and splanchnic tissues [73, 74] . If uptake of glucose by the kidney was regulated by insulin in humans as it is in dogs and rats [12, 28, 75] , the kidney could provide another explanation for the insulin resistance found in patients with chronic renal failure [76] since loss of a major target organ for insulin could result in insulin resistance. Requirements of exogenous insulin in IDDM patients who develop end-stage renal failure tend to decrease [77] . The most widely accepted explanation for this is loss of renal insulin excretion resulting in a prolonged biological half-life of the hormone [78] . However, decreased renal gluconeogenesis may be a contributing factor.
Regarding the pathogenesis of human diabetes, both IDDM and NIDDM are characterized by increased rates of glucose turnover [79] . In NIDDM, this overproduction of glucose has been established by several different experimental approaches to be predominantly the result of increased gluconeogenesis [80, 81] . According to current belief, which is based on isotope dilution experiments and the assumption that renal glucose output is insignificant, this is thought to occur exclusively in the liver. The recent observations in IDDM and indirect data for NIDDM suggest a proportionate contribution of renal glucose production to the increased endogenous glucose production in both diseases. Thus, renal gluconeogenesis conceivably is important in the pathogenesis of fasting hyperglycaemia in NIDDM.
Finally, the issue of insulin suppressing renal glucose production is important in the light of publications suggesting that systemic insulinization is as effective as portal insulinization in suppressing systemic glucose production [82] [83] [84] . If renal glucose production was sensitive to insulin, an explanation for these findings could be provided. Moreover, if renal glucose production was insulin sensitive, the insulin resistance of NIDDM could lead to overproduction of glucose by the kidney.
Summary and conclusions
In view of the evidence presented here, the traditional perception of the human kidney playing a minor role in glucose homeostasis should be abandoned. With its contribution to glucose production and glucose utilization, the kidney may be of considerable relevance in glucose counterregulation, postprandial glucose disposal, insulin resistance of uraemia and the pathogenesis of hyperglycaemia in diabetes. 
